DR. STACY GREENE M.D.
Prescription History 1003820721
Internal Medicine - Infectious Disease in New Orleans, LA

NPI Status: Active since July 28, 2006

Contact Information

2900 MAGAZINE ST
NEW ORLEANS, LA
ZIP 70115
Phone: (504) 208-2000
Fax: (833) 471-6166

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. STACY GREENE M.D., an active Infectious Disease specialist practicing in New Orleans, LA. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 144 documented patient claims. Among these therapy options, the most frequently utilized medication is Biktarvy, which accounts for 54 claims alone.

Medication Index

No matching medications currently found on file.

Apretude

Generic Formulation: CabotegravirSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
LA State Average Benchmarks
Peer Average Claims--
Peer Average 30-Day Fills--
Peer Average Days Supply--

Provider Avg Cost Per Claim

$3,480.13

State Avg Cost Per Claim

--

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to help reduce the risk of getting HIV infection. Cabotegravir belongs to a class of drugs known as integrase inhibitors. It works by blocking the virus from growing and infecting more cells. This product does not protect against other sexually transmitted infections (such as gonorrhea, syphilis). When cabotegravir is given in combination with rilpivirine, it is used to help control HIV infection. To decrease your risk of getting HIV and other sexually transmitted infections, use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Biktarvy

Generic Formulation: Bictegrav/Emtricit/Tenofov AlaSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 54
30-Day Fills 54.0
Days Supply 1,620
LA State Average Benchmarks
Peer Average Claims90.0
Peer Average 30-Day Fills91.0
Peer Average Days Supply2,714
Conservative Utilization

This provider writes prescriptions for this formulation 40.0% less frequently than the standard regional baseline metric for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $209,178.11 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,873.67

State Avg Cost Per Claim

$3,884.83

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination product is used by itself to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of 3 different drugs: bictegravir, emtricitabine, and tenofovir alafenamide. Bictegravir is called an integrase strand transfer inhibitor-INSTI. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor. Emtricitabine and tenofovir alafenamide are often called NRTIs. Bictegravir/emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Cabenuva

Generic Formulation: Cabotegravir/RilpivirineSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 23
30-Day Fills 23.0
Days Supply 680
LA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills27.1
Peer Average Days Supply803
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $141,935.44 across this reporting matrix range.

Provider Avg Cost Per Claim

$6,171.11

State Avg Cost Per Claim

$5,868.34

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to help control HIV infection. It contains 2 medications: cabotegravir and rilpivirine. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Cabotegravir is an integrase inhibitor while rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). Both drugs block the virus from growing and infecting more cells. Cabotegravir/rilpivirine is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Descovy

Generic Formulation: Emtricitabine/Tenofov AlafenamSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 424
LA State Average Benchmarks
Peer Average Claims54.0
Peer Average 30-Day Fills55.0
Peer Average Days Supply1,643
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 72.2% less volume than the regional standard for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $32,610.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,174.02

State Avg Cost Per Claim

$2,197.20

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of two different drugs: emtricitabine and tenofovir alafenamide. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor. They are often called NRTIs. This product should not be used by itself to help control HIV infection. Doing so can make your treatment less effective. Use combination treatment with at least one other HIV medication. This product is also approved in the US to help prevent HIV infection in people who have a high risk for infection. Some things that increase risk include having a partner infected with HIV, having unprotected sex, having multiple sex partners, infection with a sexually transmitted disease-STD, or use/abuse of drugs or alcohol. Emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Tivicay

Generic Formulation: Dolutegravir SodiumSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 364
LA State Average Benchmarks
Peer Average Claims69.0
Peer Average 30-Day Fills69.6
Peer Average Days Supply2,056
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 81.2% less volume than the regional standard for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $27,623.57 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,124.89

State Avg Cost Per Claim

$2,316.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Dolutegravir is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Dolutegravir belongs to a class of drugs known as integrase inhibitors. It blocks the virus from growing and infecting more cells. Dolutegravir is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Vemlidy

Generic Formulation: Tenofovir AlafenamideSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 28
30-Day Fills 28.0
Days Supply 840
LA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills32.5
Peer Average Days Supply973
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $40,378.21 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,442.08

State Avg Cost Per Claim

$1,390.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Tenofovir alafenamide is used to treat chronic hepatitis B infection, a viral infection of the liver. It works by stopping or slowing the growth of the virus. Chronic hepatitis infection can lead to serious liver damage (cirrhosis) and liver cancer. It is not known if tenofovir alafenamide can cure hepatitis B or can prevent you from passing the virus to others. Practice safer sex (such as the use of latex condoms) to lower the risk of passing the virus to others.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. STACY GREENE M.D. provides transparency into local medical care patterns within New Orleans, LA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Infectious Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.